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Object. Approximately 10% of cerebrospinal fluid (CSF) shunt operations are associated with infection and require 
removal or extemalization of the shunt, in-hospital treatment with antibiotic agents, and insertion of a new shunt. In a 
previous survey, the authors identified substantial variation in the duration of antibiotic therapy as well as the duration 
of hospital stay. The present multicenter pilot study was undertaken to evaluate current strategies in the treatment of 
shunt infection.
Methods. Patients were enrolled in the study if they had a successful treatment of a CSF shunt infection proved by 
culture of a CSF specimen. Details of their care and the incidence of culture-proved reinfection were recorded.
Seventy patients from 10 centers were followed up for 1 year after their CSF shunt infection. The initial manage­
ment of the infection was shunt extemalization in 17 patients, shunt removal and external ventricular drain insertion 
in 50, and antibiotic treatment alone in three. Reinfection occurred in 18 patients (26%). Twelve of the 18 reinfections 
were caused by the same organism and six were due to new organisms. The treatment time varied from 4 to 47 days, 
with a mean of 17.4 days for those who later experienced a reinfection compared with 16.2 days for those who did not. 
The most common organism (Staphylococcus epidermidis, 34 patients) was associated with a reinfection rate of 29% 
and a mean treatment time of 12.8 days for those who suffered reinfection and 12.5 days for those who did not.
Conclusions. Reinfection after treatment of a CSF shunt infection is alarmingly common. According to the data 
available, the incidence of reinfection does not appear to be related to the duration of antibiotic therapy.
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e r e b r o spin a l  fluid shunt implantations account for 
I  a significant number of neurosurgical admissions 
and procedures.7 Although they have resulted in dra­
matic improvements in patient survival and neurological 
function, CSF shunts are associated with several complica­
tions. One of the most common is infection, which occurs 
in nearly 10% of patients.1A5 The treatment of shunt infec­
tion usually requires removal or extemalization of the shunt 
and treatment with antibiotic agents for a period of time, 
followed by insertion of a new shunt.2-3 
The optimal duration of antibiotic therapy for infected 
shunts is not obvious from findings presented in the liter­
ature. From a review of anecdotal accounts, uncontrolled 
studies, and discussions with colleagues, it has become 
apparent that some surgeons treat CSF shunt infections for 
differing time periods. A similar variation in treatment du­
ration was identified in the responses to a case-scenario 
questionnaire sent to members of the American Society of
Abbreviations used in this paper: CSF = cerebrospinal fluid; 
EVD = external ventricular drain.
Pediatric Neurosurgeons.8 To investigate the differences in 
treatment time further, we performed a pilot study for the 
following reasons: 1) to obtain detailed information on cur­
rent methods of practice, and 2) to determine the incidence 
of recurrent shunt infection after treatment and the risk fac­
tors for recurrence.
Clinical Material and Methods
Patient Selection
We conducted a prospective multicenter observational 
study. The centers that were included in this study were 
children’s hospitals that offer care provided by pediatric neu­
rosurgeons. Patients presenting with symptoms of a shunt- 
related problem were examined according to the surgeon’s 
usual clinical practice. If there was sufficient clinical suspi­
cion of shunt infection, fluid was aspirated from the shunt, 
wound, or abdomen as indicated (that is, a “tap” was per­
formed, and the fluid was sent for microbiological examina­
tion). In patients with ventriculoatrial shunts, blood cultures 
were examined as well.
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Although the characterization of “sufficient clinical sus­
picion” was left up to the individual surgeon, the following 
scenarios usually led surgeons to perform a tap: fever asso­
ciated with symptoms or signs of shunt obstruction, unex­
plained fever after a recent shunt operation, meningismus, 
wound erythema, purulent discharge from the wound, ero­
sion of the shunt equipment through the wound or skin, ab­
dominal pseudocyst, or peritonitis.
When the clinical evidence was insufficient to be indica­
tive of one of the aforementioned conditions and the patient 
underwent a shunt revision, CSF was sent for Gram stain­
ing and culture at the time of surgery. In addition, some sur­
geons performed a tap as a routine part of the shunt evalu­
ation, even in the absence of any of these factors. In either 
of these situations the results of the fluid examination were 
used to determine eligibility for the study. The surgeon’s 
reason for performing a tap was recorded.
Patients who met the following criteria were eligible for 
the study. 1) A CSF shunt infection was present. A CSF 
shunt was defined as a device implanted to divert CSF from 
the ventricles or from an intracranial cyst to the peritoneum 
or the heart. A CSF shunt infection was defined as the iden­
tification of organisms on a Gram stain or culture of CSF ob­
tained from the shunt lumen, purulent material from around 
the shunt, abdominal fluid collection if present, or blood (in 
patients with ventriculoatrial shunts). Growth of organisms 
that appeared around the entire shunt material while cultured 
in broth was not considered an infection in the absence of 
other positive culture results. 2) Patients were younger than
19 years of age. 3) Patients had to be able to participate in 
the planned follow-up studies. 4) The expected patient sur­
vival was longer than 12 months. 5) Patients and their fam­
ilies were willing to give informed consent. Patients who re­
ceived antibiotic agents prior to undergoing a tap (which 
may have occurred when patients were referred from out­
side institutions) were assessed according to the aforemen­
tioned criteria and were still eligible to participate in the 
study if the CSF culture was positive or organisms were 
identified on a Gram stain.
Patient Population
Seventy patients were enrolled from 10 centers between 
May 2001 and June 2004. The mean patient age was 5.4 
years (range 26 days-18 years); approximately one quarter 
(23%) of the patients were younger than 1 year of age at the 
time infection was diagnosed. The proportions of male and 
female patients were equal. The most common causes of 
hydrocephalus were intraventricular hemorrhage in 21 pa­
tients, congenital hydrocephalus in 13, and myelomeningo­
cele in 10. At the time of enrollment in the study, none of 
the patients was on a regimen of immunosuppressive ther­
apy. Most patients (55) had a single ventriculoperitoneal 
shunt in place, and most (59) had distal drainage to the peri­
toneal space. Four shunts were atrial and one was pleural. 
All patients were observed for 1 year or until they experi­
enced infection recurrence. Infection recurred in 18 (26%) 
of 70 patients. In 12 patients these reinfections were caused 
by the same organism as the original infection, and in six 
they were due to a different organism.
Case Management
The participating surgeons continued their usual methods
of shunt infection treatment; the details were recorded but 
not restricted. In general, management consisted of the fol­
lowing. Broad-spectrum antibiotic therapy commenced af­
ter the tap was performed but before the results of the tap 
were available. The choice of antibiotic agent was left to the 
participating surgeon. Within 48 hours of diagnosis of shunt 
infection one of the following strategies was followed. 1) 
The shunt was removed and an EVD was inserted. 2) The 
lower end of the shunt was externalized via an incision 
along the course of the shunt. 3) A decision was made to 
treat the infection without removing the shunt equipment. 
Antibiotic therapy was adjusted based on the results of the 
Gram staining and culture and sensitivity reports when they 
became available. Other interventions, such as replacing 
the EVD or administering intraventricular antibiotic agents, 
were recorded but not restricted. Specimens of CSF were 
collected daily and sent for cell count and culture. A new 
shunt was implanted when the treating surgeon thought it 
was appropriate (that is, according to the surgeon’s usual 
practice). The antibiotic regimen following shunt insertion 
was also dictated by the surgeon’s usual practice. At follow- 
up visits, the indications for performing a shunt tap and the 
definition of shunt infection were the same as those used in 
assessing eligibility (see earlier). Investigators at each center 
obtained local institutional review board approval, and the 
data were collated and analyzed at the University of Utah.
Results
Infection Characteristics
The reason for obtaining a CSF culture was “suspicion of 
infection” in 57 patients. Six infections were diagnosed at 
the time of CSF sampling, during what was thought to be a 
shunt malfunction unrelated to an infection. The last proce­
dure performed prior to diagnosis of infection was a shunt 
insertion in 27 patients and a shunt revision in 39 patients. 
The last procedure was performed less than 6 months be­
fore diagnosis of infection in 60 of the 70 patients.
A history of shunt revisions was common in this popula­
tion. Twenty-seven patients had not undergone a shunt revi­
sion, whereas 17 patients had fewer than five previous revi­
sions and the remainder of the patients had five or more. 
Thirteen of the 70 patients had a history of shunt infection. 
Seven of the 13 had experienced shunt infection within the 
preceding 6 months, and that group had a recurrence rate of 
43% after treatment of the current shunt infection. The six 
patients who suffered an infection more than 6 months pre­
viously had a 24% recurrence rate after treatment of the 
current shunt infection.
The most common organism was Staphylococcus epider- 
midis, which caused the infection in 34 patients; nine pa­
tients were infected by Staphylococcus aureus. The other 
organisms recorded were Propionibacterium acnes, Strep­
tococcus pneumoniae, Streptococcus viridans, Escherichia 
coli, Klebsiella sp., and mixed flora.
Infection Treatment
The initial treatment of the infection was, most common­
ly, complete removal of the shunt and insertion of an EVD, 
which was done in 50 of the 70 patients. In 17 patients, the 
upper portion of the shunt system was left in situ and the
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F ig . 1. Time line and charts showing the total treatment time and the incidence of reinfection. Clean CSF refers to CSF 
that is free of infection. Rx = treatment.
distal tubing was externalized through an incision along the 
shunt track. Three patients were treated without removal of 
any shunt equipment, and given antibiotic therapy alone. In 
one of them there was a slight growth of Staphylococcus  
epideniiidis in the CSF of one specimen after 4 days of cul­
ture. This was interpreted as a possible contaminant; it was 
treated with antibiotic therapy alone and resulted in a recur­
rent infection. The second patient was found to have Strep­
tococcus pyogenes  in the blood. The distal portion of the 
shunt was in the atrium. This patient was treated with antibi­
otic agents alone, without a recurrence. In the third patient a 
growth of Staphylococcus aureus came from a wound in­
fection. This infection was treated only with antibiotic med­
ication, and the patient did not suffer a recurrence.
After the original surgical treatment of the shunt infec­
tion, 39 patients underwent additional procedures in which 
an EVD was exchanged or placed. Twenty-nine of the 39 
patients underwent a single procedure and 10 underwent 
multiple external ventricular drainage procedures. At the 
time of shunt placement, a new entry site was made in 35 
patients, and eight (23%) of these experienced a reinfection. 
In 28 patients, the same entry site was used for shunt inser­
tion, and eight (29%) of these patients suffered a reinfection.
Treatment Time
The total treatment time from diagnosis to shunt reinser­
tion is depicted in Fig. 1. It ranged from 4 to 47 days (mean 
16.5 days). The mean total treatment time for patients in 
whom reinfection developed was 17.4 days, and for those 
who did not experience reinfection it was 16.2 days.
After the CSF was found to be free of infection, treat­
ment continued from 3 to 46 days (mean 13 days; Fig. 2). 
For patients in whom a reinfection occurred, the mean du­
ration of treatment was 14 days after the CSF was found to 
be infection free and for patients who did not experience a 
reinfection it was 12.7 days. When the patients are divided 
into groups based on the length of treatment after the CSF 
was noted to be free of infection, the reinfection rate for 
those treated for 7 days or less was 20% (four of 20 pa­
tients), and the rate for those treated for longer than 7 days 
was 28% (13 of 46 patients).
Twenty-two patients completed their treatment course 
without any intervening procedures to change the EVD af­
ter the original surgical treatment. The mean total treatment 
time was 11 days (range 3-23 days). Patients in this group 
in whom a reinfection developed had been treated for a 
mean of 10.5 days, whereas patients who did not experience 
a reinfection were treated for a mean of 11.8 days. When the 
same group was analyzed according to treatment time after 
their CSF was found to be infection free, the mean treat­
ment time was 9 days (range 3-17 days) for those who ex­
perienced a reinfection and 9.1 for those who did not.
Among the 34 patients whose infection was due to Staph­
ylococcus epiderm idis, reinfection occurred in 10 (29%). 
The mean time to rid the CSF of infection was 2.7 days, and 
the mean total treatment time was 12.6 days (range 3-39 
days). The mean treatment time after the CSF was infection 
free was 10.1 days (range 3-30 days). The reinfection rate 
was 27% in patients infected by Staphylococcus epidennid- 
is who were treated for 7 days or less (four of 15 patients), 
and 28% in those who were treated for more than 7 days 
(five of 28 patients).
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Fig. 2. Time line and charts demonstrating the treatment time after clcan CSF and the incidcncc of rcinfcction.
Discussion
Because our previous observations8 were based on a 
case-scenario survey, our goal in this study was to obtain a 
more detailed picture of surgeons’ actual clinical practice. 
The most remarkable finding is the alarmingly high inci­
dence of recurrent shunt infection after treatment. Overall, 
the recurrence rate was 26%; two thirds of the recurrent in­
fections were caused by the same organism and one third 
were due to a different organism. The recurrence rate after 
the treatment of Staphylococcus ep idem udis  infections was 
29%. The most significant risk factor for recurrence of in­
fection appeared to be a history of shunt infection within 
the preceding 6 months. A similarly high recurrence rate 
was found by Kulkarni, et al.'3
The variation in the duration of antibiotic therapy is strik­
ing. This wide degree of variation occurred even among 
those patients who were not required to undergo interven­
ing procedures to change the EVD. This is in agreement 
with our previously published survey of members of the 
American Society of Pediatric Neurosurgery.8 Eighty-four 
of 129 members responded to the case-based questionnaire, 
A great deal of intersurgeon variability in the duration of 
antibiotic therapy was observed. This was also true for spe­
cific organisms. For example, the duration of antibiotic the­
rapy (after shunt removal and EVD placement) for S taphy­
lococcus epidem udis  infections ranged from 2 to 21 days.
Conclusions
Several of the findings in this pilot study deserve further 
examination. The high recurrence rate after treatment of
a shunt infection is difficult to accept, and methods to de­
crease it should be sought. Now that antibiotic-impregnated 
EVDs and shunt catheters are available, their role in the pre­
vention and management of infection needs to be evaluated. 
It is possible that the use of such an EVD during treatment 
of an infection might more rapidly or more effectively clear 
the CSF of infection. On the other hand, specimens obtained 
from such an EVD might be less likely to exhibit growth 
of bacteria, resulting in undertreatment of the infection. A 
study in which antibiotic- and non-antibiotic-impregnated 
EVDs are compared during management of an infection 
therefore seems warranted. Another possible study would 
be to evaluate the role of antibiotic-impregnated shunt cath­
eters at the time of shunt replacement after treatment of an 
infection. Such a study might be feasible given the fairly 
high recurrence rate of 26% demonstrated in this pilot study.
The extreme variability in the duration of antibiotic ther­
apy and the lack of association between treatment time and 
recurrence suggest the potential for further work as well. 
The duration of antibiotic therapy determines the duration 
of hospital stay. In some centers, patients in whom an EVD 
has been placed stay in an intensive care unit; thus the cost 
of treatment of shunt infection can be quite significant. Be­
cause of the lack of association between duration of thera­
py and recurrence, the potential to decrease treatment time 
and, therefore, decrease hospital stay should be further in­
vestigated.
Appendix
The following persons and institutions participated in The Man­
agement of Shunt Infection (MOSI): A Multicenter Pilot Study. Note
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that the participating centers are listed in order of the number of eli­
gible patients entered.
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